Appointment of Cost Auditor for the Financial Year 2026-27.

VIRUPAKSHA To Date: 27.07.2026 The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636) Sub: Outcome of Board Meeting With reference to the subject cited this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Monday, 27" July, 2026, at 04:00 p.m. at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter ended 30.06.2026. (Attached) 2. Limited Review Report for the quarter ended 30.06.2026. (Attached) 3. Appointment of M/s. PCR & Associates, Cost Accountants, as Cost Auditors of the Company for the FY 2026-27. (Details are attached as AnnexurAe) 4. Notice of the Annual General Meeting (AGM) for the financial year 2025-26. 5. Annual General Meeting for the FY 2025-26 is scheduled to be held on Friday, 21% August, 2026 at 10:30 a.m. through Video Conferencing (*VC”)/ other Audio-Visual Means (“OAVM™). 6. Approved the re-constitution of the POSH Committee of the Board with effect from today i.e. 27 July, 2026. (Details as annexed as Annexure - B) The Meeting concluded at 5:30 p.m. This is for the information and records of the Exchange, please. Thanking you. Yours faithfully, For Oxygenta Pharmaceutical Limited Balasubba Reddy Ma ‘Whole-time Director (DIN: 01998852) OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company) Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com Phone: 040-23073417, CIN: L.24110TG1990PLC012038 Y Oxygenta s VIRUPAKSHA Annexur— eA Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD-2/P/CIR/2026/1 dated January 30, 2026) Particulars Cost Auditor Reason for change viz. | Appoinument of M/s. PCR & Associates, Cost Accountants as appointment, resignation, | Cost Auditors of the Company. removal, death or otherwise Date of appointment & Terms | Date of appointment: 27.07.2026 of appointment Terms of appointment: Appointed for the Financial Year 2026- 27 at terms as recommended by the Audit Committee and approved by the Board of Directors, subject to ratification of shareholders. Brief Profile PCR & Associates is a leading Cost Accountancy firm rendering . comprehensive professional services which include Cost Audit, Management Consultancy, Tax Consultancy, Cost Accounting Services, Manpower Management, Secretarial Services etc. Disclosure of relationships | Not Applicable between directors (in case of appointment of a director) OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An ISO 9001:2015, ISO 14001:2018 and 1SO 45001:2015 Certified Company) Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com Phone: 040-23073417, CIN: L24110TG1990PLC012038 VIRUPAKSHA Annexure — B Composition of Internal Complaints Committee (ICC)/POSH Committee S no. | Name of the Member(s) Designation L. | Ms. Kurapati Divya Presiding Officer 2. | Ms. Kuchipudi Jyothi Internal Member 3. | Ms. B. Rajitha Internal Member 4. | Ms. S. Chandraleka Internal Member 5. | Ms. Yempally Sindhu Internal Member 6. | Ms. D. Rajeswari External Member OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company) Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA, E-Mail id: info@oxygentapharma.com Website: www.oxygentapharma.com Phone: 040-23073417, CIN: L24110TG1990PLC012038 OXYGENTA PHARMACEUTICAL LIMITED CIN : L24110TG1990PLCO12038 Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State Corp Office: Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@oxygentapharma.com, Phone Number: 040- 23355938 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 (Rupees in Lakhs except for EPS), Quarter Ended YEAR ENDED Particulars- 30-06-2026 | 31-03-2026 | 30-06-2025 | 31-03-2026 (Unaudited) (Audited) (Unaudited ) (Audited) Revenue (a) [Revenue from operations 3,699.69 4,961.40 151347 11,298.19 (b) |Other Income 233 17.29 1691 2858 Total revenue 3,702.02| 4,978.69 153037 | 1132677 Expenses (a) |Cost of materials consumed 2,340.08 4,654.43 1,565.88 11,033.85 (b) |Changes in inventories of finished goods, work- in-progress and stock-in-trade 684.48 (334.13) (7034) (82030) (c) |Employee benefit expense 19533 171.79 200.19 76449 (d) |Finance Costs 24550 18081 6284 §760 (e) [Depreciation and amortisation expense 61.84 (24.11) 8473 23226 () |Other expenses 425.10 457.88 500,69 1,856.81 Total expenses 395275 5106.67 234399 | 1354479 Profit before exceptional items and tax(1-2) (250.73)| (127.97) (813.62) (2218.02) Exceptional Income/(expenses) = - (1.18) Profit / (Loss) before tax (3+ 4) (250.73), (127.97) (814.80)| (2,218.02) Tax (expense)/credit : a)Current Tax R - R b)Deferred Tax (40.35) 4242 (204.19) (460.86) Prior period Income tax adjustment Net Profit / (Loss) for the period (5+ 6) (210.37) (170.39) (610.61) (1,757.17) Other Comprehensive Income (@) [() Items that will not be reclassified to profit or loss - 7099 - 7099 (ii) Tax on items that will not be reclassified to profit or loss - (10.46)] - (18.46) (b) |(i) Items that will be reclassified to profit or loss = - - = (if) Income tax relating to items that will be reclassified to profit or loss - - - - Total Other Comprehensive Income/(loss) - 52.54 . 52.54 Total Comprehensive Income(7+8) (210.37) (117.86) (610.61)| (1,704.63) Paid-up equity share capital (face value Rs. 10/- each ) 369835 369835 360835 360835 Earnings per equity share ( of Rs.10/- each ) (not annualised): (a) Basic (0.57) (2.86) (b) Diluted (0.57), (2.86), NOTES: 1 The financial results of the company have been prepared in accordance with Indian Accouting Standards (ind AS) notified under the companies (indian Accouting standards) Rules, 2015 as amended by the companies (Indian Accouting standards) (Amendment) rules,2016. 2 The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 27th July 2026 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township, Hyderabad, Rangareddy, Telangana, India, 500037 3 The Statutory Auditors of the Company have carried out “Limited Review" of the above unaudited financial results and their Report has been placed before the board meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015 4 Total Revenue for the current quarter reported Rs. 3699.69 Lakhs compared to Rs. 1513.47 lakhs for the corresponding quarter of the previous year. 5 The Loss before tax for the current quarter is Rs.250.73 Lakhs compared to Loss Before tax of Rs.814.80 Lakhs for the corresponding quarter of the previous year. 6 The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS- 108 is not made. 7 The results for the quarter ended 30 June 2026 are also available on the bomaba [Showing first 8,000 characters — download PDF for full document]